
Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia
Viatris Reports Positive Top-Line Results from Pivotal Phase 3 VEGA-3 Trial of MR-141 for Presbyopia, Underscoring Its Potential as a Non-Invasive Vision Correction Therapy Viatris, a global healthcare company committed to increasing access to high-quality medicines and health solutions worldwide,…